Alnylam 制药 ALNY
$155.94 −$0.72 (-0.46%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $155.42 -0.33%
开盘$155.22
昨收$156.66
当日区间$154.30 – $159.45
成交量2.83M
市值$20.89B
市盈率(TTM)8.1
股息率–
财报
财报日平均波动±7.8%近16次财报
收涨次数7 / 1644% 的概率
最佳反应+15.4%
最差反应-28.3%
每次财报后次日股价变动
| 季度 | 财报日期 | 时段 | 隐含波动 | 实际波动 | 较隐含波动 |
|---|---|---|---|---|---|
| 2026/Q3 | 29 Oct 2026 | Pre Market | ±11.2% | -25.13% | 超出定价预期 |
| 2026/Q2 | 30 Jul 2026 | Pre Market | ±10.1% | -28.31% | 超出定价预期 |
| 2026/Q1 | 30 Apr 2026 | Pre Market | ±7.8% | +2.76% | 符合区间 |
| 2025/Q4 | 12 Feb 2026 | Pre Market | ±6.4% | -4.28% | 符合区间 |
| 2025/Q3 | 30 Oct 2025 | Pre Market | ±10.2% | -6.65% | 符合区间 |
| 2025/Q2 | 31 Jul 2025 | Pre Market | ±8.3% | +15.43% | 超出定价预期 |
| 2025/Q1 | 1 May 2025 | Pre Market | ±9.1% | -3.08% | 符合区间 |
| 2024/Q4 | 13 Feb 2025 | Pre Market | ±7.1% | -0.40% | 符合区间 |
| 2024/Q3 | 31 Oct 2024 | Pre Market | ±8.4% | -5.29% | 符合区间 |
| 2024/Q2 | 1 Aug 2024 | Pre Market | ±7.8% | +13.12% | 超出定价预期 |
| 2024/Q1 | 2 May 2024 | Pre Market | ±8.8% | +0.23% | 符合区间 |
| 2023/Q4 | 15 Feb 2024 | Pre Market | ±5.4% | -10.19% | 超出定价预期 |
| 2023/Q3 | 2 Nov 2023 | Pre Market | ±7.4% | +2.89% | 符合区间 |
| 2023/Q2 | 3 Aug 2023 | Pre Market | ±7.3% | +1.65% | 符合区间 |
| 2023/Q1 | 4 May 2023 | Pre Market | ±8.5% | +2.95% | 符合区间 |
| 2022/Q4 | 23 Feb 2023 | Pre Market | ±9.9% | -2.42% | 符合区间 |
"隐含波动"指财报发布前期权市场定价的预期波幅。"波动"指财报发布后首个交易日的股价变化。
营收构成
2026/Q2 季度
按业务线
基本面
最新报告季度:Q2, ended Jun 2026
营收$1.29B+66.9% YoY
营业利润$231.44M+1,528.7% YoY
净利润$164.49M+327.7% YoY
摊薄每股收益$1.21+320.0% YoY
自由现金流$292.04M+152.8% YoY
经营现金流$326.72M
营收,近8个季度
净利润,近8个季度
盈利能力与资产负债表
毛利率79.7%
营业利润率20.8%
净利率16.1%
净资产收益率96.6%
资产收益率15.3%
投入资本回报率42.2%
流动比率3.05
负债/资产比率75.6%
现金及投资$3.31B
总负债$1.22B
净现金(净负债)$2.09B
自由现金流/营收17.1%
暂无评论——快来第一个聊聊 ALNY。
登录后参与讨论。